Back to top
more

Merck & Co. (MRK)

(Delayed Data from NYSE)

$85.98 USD

85.98
12,384,464

-0.30 (-0.35%)

Updated Oct 31, 2025 04:00 PM ET

After-Market: $86.10 +0.12 (0.14%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.93%
2Buy18.16%
3Hold10.10%
4Sell5.63%
5Strong Sell2.84%
S&P50011.45%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 32% (165 out of 243)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

MRK Beats Q3 Earnings Estimates, Narrows 2025 Sales View, Stock Down

by Zacks Equity Research

Merck tops Q3 earnings and revenue estimates on strong oncology, new drugs and animal health sales, while narrowing its 2025 revenue outlook.

Zacks Equity Research

Merck (MRK) Reports Q3 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

The headline numbers for Merck (MRK) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Equity Research

Merck (MRK) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Merck (MRK) delivered earnings and revenue surprises of +9.32% and +1.24%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Should You Buy, Hold, or Sell GILD Stock Ahead of Q3 Earnings?

by Zacks Equity Research

Gilead Sciences gears up for Q3 results with strong HIV gains and new FDA approvals, amid challenges in its Cell Therapy business.

Kinjel Shah headshot

Buy, Sell or Hold MRK Stock Ahead of Q3 Earnings? Things to Know

by Kinjel Shah

MRK faces pressure from weak vaccine sales and rising competition, but strong oncology growth and new launches could support a rebound.

Kinjel Shah headshot

3 Cancer-Focused Stocks Showing Strong Pipeline Progress

by Kinjel Shah

Relay, Fate and Verastem advance promising cancer therapies, strengthening their pipelines in a rapidly evolving oncology market.

Zacks Equity Research

Are You Looking for a High-Growth Dividend Stock?

by Zacks Equity Research

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.

Zacks Equity Research

Dr. Reddy's Q2 Earnings Beat Estimates, Generics Sales Boost Revenues

by Zacks Equity Research

RDY posts a Q2 earnings and revenue beat as global generics drive growth, while new launches and biosimilar advances shape its pipeline.

Ahan Chakraborty headshot

What's in Store for These 5 Pharma Bigwigs This Earnings Season?

by Ahan Chakraborty

As earnings season accelerates, pharma heavyweights LLY, MRK, ABBV, BMY and GILD prepare to reveal their Q3 results amid a strong sector start.

Kinjel Shah headshot

JNJ vs. MRK: Which Blue-Chip Pharma Stock Should Be in Your Portfolio?

by Kinjel Shah

J&J's diversified growth, strong pipeline, and robust balance sheet position it as a steadier long-term pick over Merck's Keytruda-dependent outlook.

Zacks Equity Research

Merck (MRK) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates

by Zacks Equity Research

Get a deeper insight into the potential performance of Merck (MRK) for the quarter ended September 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.

Kanishka Das headshot

Merck's Non-Oncology Drugs Q3 Performance: What to Expect

by Kanishka Das

MRK expects new products like Capvaxive, Winrevair, and the Animal Health business to support its top-line growth in the third quarter.

Sundeep Ganoria headshot

Here's How Eli Lilly's Oncology Drugs Are Poised Ahead of Q3 Earnings

by Sundeep Ganoria

LLY's oncology portfolio, led by Verzenio, is set for double-digit growth as investors eye Q3 results beyond its obesity drugs.

Zacks Equity Research

Merck (MRK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

SMMT's Q3 Loss Wider Than Expected, Stock Down on Study Amendments

by Zacks Equity Research

Summit Therapeutics posts a wider Q3 loss as costs surge and investors react to protocol changes in a key ivonescimab study.

Ekta Bagri headshot

Will BMY's Growth Portfolio Drive Third-Quarter Results?

by Ekta Bagri

Bristol Myers leans on new drugs like Opdivo and Reblozyl to offset pressure from generics as its Growth Portfolio drives stability.

Zacks Equity Research

Merck (MRK) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Merck (MRK) closed the most recent trading day at $86.32, moving +1.8% from the previous trading session.

Sundeep Ganoria headshot

Here's What to Expect From AbbVie's Oncology Segment in Q3 Earnings

by Sundeep Ganoria

ABBV's oncology lineup, spanning blood and solid tumor drugs, faces modest Q3 growth as new launches offset Imbruvica's decline.

Kanishka Das headshot

Will Declining Gardasil Sales Ail MRK's Top Line in Q3 Earnings?

by Kanishka Das

Merck faces a sharp Gardasil slowdown as weak demand in China and Japan affects sales of the vaccine.

Zacks Equity Research

Is Trending Stock Merck & Co., Inc. (MRK) a Buy Now?

by Zacks Equity Research

Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks Equity Research

Merck (MRK) Declines More Than Market: Some Information for Investors

by Zacks Equity Research

In the closing of the recent trading day, Merck (MRK) stood at $84.81, denoting a -1.04% move from the preceding trading day.

Ekta Bagri headshot

BMY Slips Below 50-Day SMA: Buy, Sell or Hold the Stock?

by Ekta Bagri

Bristol Myers stock slips below its 50-day average as generic pressure, high debt, and trimmed earnings outlook weigh on sentiment

Mark Vickery headshot

Top Stock Reports for Apple, Eli Lilly & Visa

by Mark Vickery

Apple's strong Services growth, Eli Lilly's GLP-1 momentum, and Visa's digital expansion headline today's top stock reports.

Zacks Equity Research

Will Merck (MRK) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Equity Research

Here's Why Merck (MRK) is a Strong Momentum Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.